Brief: Carsgen Therapeutics Says NMPA Accepted New Drug Application For Satricabtagene Autoleucel
26/06/2025 02:28
June 26 (Reuters) - CARsgen Therapeutics Holdings Ltd 2171.HK: NMPA ACCEPTED NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL FOR TREATMENT OF ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA Further company coverage: 2171.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer